Leap reports sirexatamab PFS benefit in CRC subgroups; workforce cut 75%, strategic review

CYPHERPUNK TECHNOLOGIES INC.

DeFianCe study: in high-DKK1 pts (upper quartile), median PFS 9.36 vs 5.88 mo (HR 0.47, p=0.024); ORR 44% vs 15.8% (p=0.015).
VEGF-naïve pts: median PFS 11.2 vs 8.34 mo (HR 0.61, p=0.038); ORR 55.1% vs 32.6% (p=0.012).
Full population ORR by BICR 33% vs 20.2% (p=0.0203); median PFS 9.2 vs 8.31 mo (HR 0.84, p=0.1749) not significant.
Board initiates strategic alternatives review; Raymond James engaged as advisor; workforce reduction of ~75% with $3.2M severance costs.
COO (Lawlor) terminated June 30, CMO (Sirard) terminated July 31; cash $32.7M (Mar 31).

item 2.05item 5.02item 5.07item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Cyndi Sirard, MD

Chief Medical Officer

CYPH · CYPHERPUNK TECHNOLOGIES INC.

Effective: 2025-07-31
Filed: Jun 23, 2025 23:59 UTC

Cyndi Sirard, MD will be terminated without cause from her position as the Company’s Chief Medical Officer, effective on or about July 31, 2025

Departed

Augustine Lawlor

Chief Operating Officer

CYPH · CYPHERPUNK TECHNOLOGIES INC.

Effective: 2025-06-30
Filed: Jun 23, 2025 23:59 UTC

Augustine Lawlor will be terminated without cause from his position as the Company’s Chief Operating Officer, effective June 30, 2025

Source: SEC EDGAR

accession 0001104659-25-061385

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.